Free press releases distribution network?

Agency / Source: Intas Biopharmaceuticals Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Intas Biopharmaceuticals Ltd Plans Manufacturing Facility For Monoclonal Antibodies - Company to invest Rs. 160 crores for recombinant Mammalian platform product; signs MoU with Government of Gujarat at the recently concluded Vibrant Gujarat Global Investors Summit 2009
Intas Biopharmaceuticals Ltd Plans Manufacturing Facility For Monoclonal Antibodies

 

PRZOOM - /newswire/ - Ahmedabad, Gujarat, India, 2009/01/19 - Company to invest Rs. 160 crores for recombinant Mammalian platform product; signs MoU with Government of Gujarat at the recently concluded Vibrant Gujarat Global Investors Summit 2009.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Intas Biopharmaceuticals Limited, India’s leading biotechnology company, signed a Memorandum of Understanding (MoU) with Government of Gujarat for setting up a separate manufacturing facility for Monoclonal Antibodies (MAbs), a recombinant mammalian platform product. The company will invest Rs 160 crores towards setting up a manufacturing facility at Sanand near Ahmedabad. The facility, dedicated for Monoclonal Antibodies, will undertake large-scale manufacturing of the recombinant product with a capacity of 5000L in phases.

Speaking at the MoU signing ceremony at the recently concluded Vibrant Gujarat Global Investors Summit 2009, MR. MANI IYER, EXECUTIVE DIRECTOR, INTAS BIOPHARMACEUTICALS LIMITED, said, “Company has acquired 23,000 square meter of land at the Matoda village in Sanand and has initiated the Engineering Design Phase for the project. Government of Gujarat would facilitate the company to obtain necessary permissions / registration and would help to avail incentives under various schemes announced by the State / Central Government.
We are seeking government approval for utilizing an alternative source of energy for fulfilling our power requirements for this project. Further, we are looking for necessary regulatory clearances, permissions and registrations from the State Government.”

In the area of Research & Development pertaining to recombinant products, the company is developing Novel Drug Delivery System for proteins, a cloning facility, introducing novel production platforms, developing MAbs and recombinant products (cytokines, hormones and blood factors). The company, in a planned and phase-wise manner, will screen technologies / new molecules and identify the most promising ones, prioritizing them on the basis of their business potential and compatibility. IBPL is planning to generate clones for commercial production of protein using state-of-the-art technologies to improve yields, quality as well as adopting novel expression systems with an objective to build Intellectual Property over the long run. MAbs has strong potential of generating IP in terms of patents and could provide a novel platform for delivery of many of the protein therapeutics.

DR. DHANANJAY PATANKAR, CHIEF TECHNICAL OFFICER, INTAS BIOPHARMACEUTICALS LIMITED, said, “The commercial production at the proposed MAbs facility is likely to commence by 2011. We have initiated the necessary technical studies for the project. The setting up of MAbs facility in Gujarat is one-of-its-kind of initiative for the state that has always welcomed and promoted new technology initiatives from Intas Biopharmaceuticals.
Our association with Government of Gujarat is a long-standing commitment to deliver superior technology and quality recombinant products to people. Since our inception in 2000, Government has supported us in each of our initiatives and we look forward to receive proactive assistance and support from them.”

As far as manufacturing activity is concerned, IBPL is indigenously manufacturing and marketing bio therapeutic drugs – GCSF, Interferon, Erythropoietin and PEG-GCSF. The company’s venture into manufacturing of MAbs is backed by necessary infrastructure to carry out R&D activity and a dedicated team of technical professionals.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Intas Biopharmaceuticals Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Intas Biopharmaceuticals Ltd Plans Manufacturing Facility For Monoclonal Antibodies

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Siddharth J. Baad - IntasBiopharma.co.in 
+91 27 17660100 siddharth.baad[.]intasbiopharma.co.in
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Intas Biopharmaceuticals Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Intas Biopharmaceuticals Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  BizJobs.com

Visit  Triggr & Bloom

Visit  La Bella Bakery Artisan Bakery Arizona







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today